Osteosarcoma Webinar Series: Janeala Morsby, PhD, a postdoctoral associate at St. Jude Children’s Research Hospital, discusses her OutSmarting Osteosarcoma funded work focused on exploring the mechanism of synergy of the dual inhibition of ATM and PARP for the treatment of pediatric osteosarcoma.
Janeala Morsby hails from the beautiful island of Jamaica, where she was born and raised in Port Antonio, Portland. Her journey to the United States began when she received a full honors scholarship to attend Claflin University, where she completed her Bachelor of Science in Biochemistry, summa cum laude. She then went on to complete her PhD at the University of Notre Dame under the supervision of Dr. Bradley Smith. At the University of Notre Dame, her work focused on the detection of hypoxia in cancer cell models, in addition to diagnostics and imaging. She is now a postdoctoral associate at St. Jude Children’s Research Hospital (SJCRH) in Dr. Lillian Guenther’s lab. At SJCRH, her work focuses on exploring the mechanism of synergy of the dual inhibition of ATM and PARP for the treatment of pediatric osteosarcoma. She is very passionate about the proposed research project and hopes that the findings of the proposed work will be beneficial to pediatric osteosarcoma patients.
Dr. Kelly Makielski and Dr. Jaime Modiano from the University of Minnesota join us on OsteoBites to discuss comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis.
They are investigating extracellular vesicle (EV) transcriptomic profiles as minimally invasive biomarkers in canine and pediatric osteosarcoma in two ongoing studies. In the Canine Osteosarcoma Early Detection (COED) study, they are sequencing EV RNA from otherwise healthy dogs in breeds at elevated risk of osteosarcoma to identify gene signatures for the early detection and risk assessment of osteosarcoma. In parallel, they are conducting the KIDsCAN study, where we are sequencing EVs from pediatric osteosarcoma patients to identify prognostic signatures that could ultimately guide treatment intensity, aiming to minimize long-term therapy-associated morbidity without negatively impacting survival. Preliminary results from COED will be shared, along with how their comparative approach is helping to guide the KIDsCAN study.
Kelly M. Makielski, DVM, DACVIM (SAIM) is an Assistant Professor of Small Animal Internal Medicine at the University of Minnesota College of Veterinary Medicine and Masonic Cancer Center. Her research focuses on extracellular vesicle (EV) biology and comparative oncology, using naturally occurring cancers in dogs to inform human cancer biology and treatment. She is the recipient of an NIH K01 investigating EV–based biomarkers for osteosarcoma prognosis in pediatric osteosarcoma, to guide personalized therapy and reduce treatment-related morbidity.
Dr. Jaime Modiano holds the Alvin and June Perlman Endowed Chair of Animal Oncology and is director of the Animal Cancer Care and Research Program of the College of Veterinary Medicine and the Masonic Cancer Center, University of Minnesota. He completed his training through the Veterinary Medical Scientist Training Program (VMD, PhD) at the University of Pennsylvania, and he followed it with a residency in Clinical Pathology at Colorado State University and a post-doctoral fellowship at the National Jewish Center for Immunology and Respiratory Medicine. Before joining the University of Minnesota, he served on the faculties of Texas A&M University and the University of Colorado Health Sciences Center. Dr. Modiano has also worked in the private sector, as founder of several start-up companies, and as Director of Cancer Immunology and Immunotherapy for the Donald Monk Cancer Research Foundation. Through his research, Dr. Modiano seeks to understand how and why cancer happens and to develop strategies for improving the health and well-being of companion animals and humans alike.
This one’s for anyone who’s ever had a hospital night that felt straight out of a horror movie. In Spooky Sarcoma Stories, four young osteosarcoma survivors — Sammy, Alejandro, Inaaya, and Max swap their wildest, scariest, and most surreal treatment memories, like the time Alejandro thought the IV tower was a robot monster, Max’s feeding tube removal turned into a “murder mystery,” Inaaya woke up to chemo-soaked sheets, and Sammy faced a limb salvage surgery that went sideways. It’s honest, a little dark, sometimes funny, and totally real. Because osteosarcoma doesn’t need ghosts to be spooky.
Osteosarcoma Webinar Series: Alanna Church, MD, Associate Director, Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital, Assistant Professor of Pathology at Harvard Medical School, and Conference Cochair joins us on OsteoBites to discuss insights and higlights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer—From Biology to Breakthrough Therapies, September 25-28 in Boston.
Dr. Church is currently a Molecular and Pediatric Pathologist at Boston Children's Hospital, where she is a founder and associate medical director of the Laboratory for Molecular Pediatric Pathology (LaMPP). She is an Assistant Professor of Pathology at Harvard Medical School, the Program Director for the Harvard Molecular Genetic Pathology Fellowship, and the incoming Chair of Clinical Practice for the Association for Molecular Pathology. Her clinical and research work focuses on bringing molecular testing to the clinical care of children with cancer. Through institutional projects (the Profile study, GAIN consortium study), she has profiled thousands of children's tumors and has used these results to make real-time impacts on their diagnoses and treatments. She is involved in national initiatives to improve the quality and access to molecular testing for children with cancer, including the NCI-funded Count Me In Study (Dana Farber, Broad Institute), the National Comprehensive Cancer Network, the National Institutes of Health, and the Children's Oncology Group.
Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.
Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children’s Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children’s Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.
In an inspirational episode of osTEAo, hosts Mia and Sammy honored the memory of their late friend and co-host, Camille Wahl. As one of the original founders of the podcast, Camille envisioned osTEAo as a space where adolescents and young adults affected by osteosarcoma could share their stories and find connection. Her legacy as both a friend and an advocate continues to inspire the mission of the podcast: raising awareness, building community, and reminding young people facing cancer that they are not alone.
Sloane, Mackenzie, and Alejandro joined Mia and Sammy in this episode to reflect on the many ways that pain can be transformed into purpose. Though cancer often brings hardship, survivors and families are finding ways to channel those difficult experiences into advocacy. Whether it’s raising awareness through initiatives like gold bows, supporting efforts to expand access to clinical trials, or simply showing up for someone in treatment, each act of advocacy helps strengthen the community and spark positive change.
Much of the conversation centered on the power of sharing stories and small acts of advocacy. Speaking honestly about the cancer experience helps others feel seen and understood, and even the smallest gestures can make a meaningful difference. These simple, everyday actions remind us that advocacy isn’t only about big campaigns or policy change. It's also about kindness, connection, and making sure no one feels alone.
In the end, the episode was both a tribute and a reminder of what matters most: community, compassion, and hope. Camille’s vision shines through in every story shared and every effort to make things better for others. Even in the face of loss, the osTEAo team showed how pain can be carried forward with love and turned into something purposeful.
Osteosarcoma Webinar Series: Yanding Zhao, PhD to discuss how Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes.
Osteosarcoma (OS) is notable for extreme chromosomal instability (CIN) and molecular heterogeneity, which have hindered therapeutic progress. To address this, the lab performed longitudinal and multi-modal profiling of 91 tumors from 71 pediatric patients, integrating whole-genome and transcriptome sequencing with ATAC-seq and Hi-C in matched cell lines. Their analyses revealed that key driver mutations, including TP53, are fixed early and persist through progression. Over 80% of tumors exhibited complex structural alterations—such as chromothripsis, kataegis, loss of heterozygosity, and ecDNA amplification—with MYC enhancer hijacking linked to chemoresistance. They identified a high-risk evolutionary trajectory marked by homologous recombination deficiency (HRD)-like signatures in the absence of BRCA mutations. These tumors showed focal duplications at fragile sites, early whole-genome doubling, high TP53 mutation burden, and sensitivity to PARP inhibition—highlighting a potential therapeutic vulnerability. Together, these findings define a replication stress–driven model of OS evolution, shaped by early chromosomal remodeling and ecDNA-mediated oncogene activation, with implications for biomarker development and precision treatment strategies.
Dr. Yanding Zhao is a postdoctoral researcher at Stanford University in the lab of Dr. Christina Curtis. He earned his PhD in Genetics from Dartmouth College, where he began developing computational tools to understand how genome instability disrupts gene regulation in cancer. At Stanford, his research focuses on pediatric osteosarcoma. By combining genome sequencing, 3D chromatin mapping, and spatial transcriptomics, he studies how tumors evolve, resist treatment, and evade the immune system. Dr. Zhao works closely with clinicians and scientists to help turn these discoveries into potential new therapies. He is honored to be part of the MIB Agents community and looks forward to sharing his work in a way that resonates with patients, families, and advocates.
Bio
Osteosarcoma Webinar Series: Brian Ladle, MD, PhD, Assistant Professor of Oncology and Pediatrics at The Johns Hopkins University School of Medicine, joins us on OsteoBites to discuss deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma.
We have learned that more engagement of the immune system and osteosarcoma results in better outcomes - even when patients are given standard chemotherapy. We have found that drugs that activate the STING pathway in osteosarcoma tumors result in greater immune cell invasion into the tumors. This corresponds with improved outcomes when combined with chemotherapy and other immunotherapies. Dr. Ladle will discuss these findings and what steps we are taking to bring this closer to clinical trials for osteosarcoma patients.
Dr. Brian Ladle is a pediatric oncologist, sarcoma specialist, and immunotherapy researcher at Johns Hopkins University. His research centers around the goal of generating potent immune responses against pediatric sarcoma tumors - especially osteosarcoma. Ongoing projects encompass preclinical work using osteosarcoma mouse models and osteosarcoma clinical trials in both dogs and humans. He really believes immunotherapy approaches can be effective against osteosarcoma and will become a key piece to "Make It Better" for osteosarcoma patients.
Dating after cancer is… complicated. Scars, body changes, medical baggage - it’s not exactly the stuff of rom-coms. In The Fault in Our Scars, OsteoWarriors Elise, Gillian, Matthew, Mia, and Sammy, get real (and a little irreverent) about navigating first dates, deciding when to drop the “I had cancer” bomb, and handling everything from awkward silences to partners who totally miss the mark.
They share the bad (ghosting, weird comments, dating-app disasters), the good (finding people who actually get it), and the surprising moments that make it all worth it. It’s a candid, funny, and sometimes brutally honest look at love, relationships, and self-acceptance when cancer is part of your story.
Osteosarcoma Webinar Series: Amanda Marinoff, MD, a physician-scientist from UCSF will discuss clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group.
Despite decades of research, osteosarcoma remains one of the few pediatric cancers without validated molecular biomarkers to guide treatment. The Clinical Biomarkers for Osteosarcoma Stratification (cBOSS) initiative is an international effort to change that. Modeled after a successful framework in Ewing sarcoma, cBOSS convened experts from North America and Europe to systematically evaluate emerging molecular features with the greatest potential for near-term clinical translation. Through a series of structured sessions, the group assessed the biological plausibility, clinical relevance, and implementation feasibility of candidate classifiers across five domains: genomic, transcriptomic, epigenetic, immune, and circulating analytes. This webinar will provide an overview of the cBOSS approach, key findings to date, including the maturity of circulating tumor DNA and MYC amplification as prognostic tools, and the path forward for incorporating molecular stratification into future clinical trials. The goal: to move beyond one-size-fits-all therapy and build a precision medicine framework for osteosarcoma.
Dr. Amanda Marinoff is a pediatric oncologist and translational researcher at UCSF, where she focuses on developing molecular biomarkers to improve risk stratification and treatment for children and young adults with osteosarcoma. She co-leads the international cBOSS initiative (Clinical Biomarkers for Osteosarcoma Stratification), which brings together experts across North America and Europe to evaluate and prioritize emerging classifiers for clinical use. Her research aims to bridge the gap between genomic discovery and therapeutic application, advancing precision medicine approaches for patients with high-risk disease. Dr. Marinoff earned her medical degree from Harvard Medical School, completed her pediatrics residency at Boston Children's Hospital, and completed her pediatric hematology/oncology fellowship at UCSF Benioff Children’s Hospital. She is an active member of the pediatric solid tumor and early-phase clinical trials groups at UCSF.
Osteosarcoma Webinar Series: Karen E. Pollok, PhD, and Pankita H. Pandya, PhD, from the Indiana University School of Medicine, join us on OsteoBites to discuss their work exploring CDK4/6i, particularly in the context of BET inhibition, as a therapeutic option for pediatric OS, regardless of RB status.
Hyperactivation of cyclin-dependent kinases 4 and 6 (CDK4/6) has been identified as an actionable molecular signature in pediatric and AYA OS patients at the Indiana University School of Medicine and others. While targeting CDK4/6 has shown promise in significantly reducing tumor progression in many cancers, resistance to CDK4/6 inhibition remains a challenge. To maximize CDK4/6 inhibitor (CDK4/6i) efficacy, a combination therapy will likely be required to mitigate emergence of resistance. Moreover, retinoblastoma proficiency (RB+) has been used as a biomarker to predict response and stratify patients for treatment with CDK4/6 inhibitors in other cancers. This is concerning in the context of OS, since over 70% of OS patients harbor a retinoblastoma deficiency (RB-). Therefore, validation of RB as a biomarker of therapeutic response to CDK4/6 inhibition in OS is needed. The lab's objective in these investigations is to identify rational drug combinations that enhance efficacy of CDK4/6 inhibition, and test prioritized combinations in both RB+ and RB- OS models. Their findings support further exploration of CDK4/6i, particularly in the context of BET inhibition, as a therapeutic option for pediatric OS, regardless of RB status.
Dr. Pollok is the Associate Director of Basic Science and Director of the Preclinical Modeling and Therapeutics Shared Resource Facility for the IU Simon Comprehensive Cancer Center (IUSCCC). Dr. Pollok works with cancer research laboratories in the IUSCCC to enhance programmatic science focused on translation to the clinic. In her own lab, she leads a team-oriented research program that brings together basic scientists and clinicians focused on finding cures for aggressive cancers such as sarcomas and brain tumors. Her team utilizes multi-omics data to prioritize the testing of novel combination therapies and has developed over 60 tumor models from pediatric and adolescent patients treated at the Riley Hospital for Children IU Health. In collaboration with Dr. Pankita Pandya and the Pediatric Precision Genomics Program, they employ multi-omics data from these models to focus on testing new molecularly-guided targeted therapies. Their goal is to understand the mechanisms behind therapy-mediated tumor efficacy and emerging resistance.
Dr. Pandya is heavily involved in translational team science, where she works in partnership with the Pediatric Precision Genomics Program at the Riley Hospital for Children at IU Health, as well as under the mentorship of Dr. Karen E. Pollok at the Herman B Wells Center. Her research initiatives involve testing novel targeted therapies for improving therapeutic outcomes while minimizing toxicity in pediatric and young adult solid cancers like sarcomas. As a genomics data scientist, she has training in multi-omics data management and mining. Additionally, Dr. Pandya has extensive expertise in in-vivo modeling of aggressive pediatric sarcomas. Such skillsets have enabled Dr. Pandya to identify risk signatures, biomarkers of therapeutic response, and other clinically-relevant therapeutic vulnerabilities in pediatric sarcoma patients for functional validation using molecularly characterized preclinical models that our translational team has developed.
In this powerful new episode of osTEAo, our AYA (Adolescent and Young Adult) cancer community gets real about toxic positivity - the idea that you have to "stay positive" no matter what you're going through, and while it's often well-meaning, it can leave patients feeling unseen, isolated, and emotionally shut down.
In this candid and emotional conversation, OsteoWarriors share how constant encouragement to be upbeat, especially during chemotherapy, surgeries, or major life changes can invalidate their real struggles.
The conversation dives into what it means to truly support someone with cancer, not by “fixing” their mood but by offering thoughtful accommodations, inclusion without pressure, and support that meets people where they really are.
Kelly Faulk, MD, a pediatric oncologist at Children's Hospital Colorado Center for Cancer and Blood Disorders, joins us on OsteoBites to review the open phase 1/1b clinical trial evaluating the combination of losartan and sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (NCT03900793), including preclinical rationale from canine clinical trials and the trial's design, eligibility, and status.
Dr. Kelly Faulk is a pediatric oncologist at Children's Hospital Colorado Center for Cancer and Blood Disorders, where her clinical and research focus is the development of early-phase clinical trials to investigate promising new agents for high-risk pediatric cancers. She is on the Experimental Therapeutics Program (ETP) team and serves as the leader of the High-Risk Leukemia/Lymphoma Program. She has developed and leads several early-phase clinical trials and serves as site principal investigator for numerous others. She completed her medical training at the University of Colorado School of Medicine, did her pediatric residency and pediatric hematology/oncology/bone marrow transplant fellowship at Children's Hospital Colorado, and also completed an additional fellowship in Experimental Therapeutics at Children's Hospital Colorado. She met her wonderful husband Wade in medical school, and they have 3 great kids who keep them busy.
OsteoBites welcomes Yingqi Hua, MD from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine to discuss his work on molecular subtyping of osteosarcoma, ecDNA, and more.
Dr. Hua has been engaged in basic and clinical research of malignant bone tumors for more than 10 years, focusing on the individualized comprehensive treatment of advanced bone tumors, and is committed to transforming research results through clinical research. His research interests include 1. Multi-omics study of osteosarcoma: Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. 2. Epigenetic study of bone tumors: the function of histone mutation and the function of different histone methylation modification. 3. Drug screen: Screening sensitive drugs by patient derived xenograft(PDX) and explore the mechanism of drug action. 4. Clinical trial of advanced stage sarcomas based on precision medicine.
In this special Mother's Day edition of osTEAo, Mia, Sammy, and Elise open up about a topic that’s often left unspoken but is profoundly personal—fertility and infertility within the AYA cancer community. With honesty and vulnerability, they share their experiences navigating fertility challenges in the wake of a cancer diagnosis, including the emotional strain of tough conversations with family members, the often-overlooked financial barriers to parenthood, and the mental and emotional load that comes with planning for a future that feels uncertain.
They dive deep into what it means to grieve lost possibilities, celebrate alternative paths to building a family, like adoption or being a meaningful figure in a child’s life, and explore how cancer reshapes the ways we think about legacy, impact, and nurturing others. This episode isn’t just about biology; it’s about identity, agency, and finding power through knowledge and community.
Whether you're grappling with fertility decisions, supporting someone who is, or simply seeking space to feel seen and understood, this conversation offers comfort, courage, and connection. Tune in and be reminded: you’re not alone, your voice matters, and there's strength in sharing the journey.
Matteo Trucco, MD, pediatric oncologist, Director of the Children’s Cancer Innovative Therapy program at the Cleveland Clinic, and chair of the MIB Agents Scientific Advisory Board joins us on OsteoBites to provide a preview of the FACTOR 2025 scientific panels in lay person terms with a brief overview of vocabulary and terms as a helpful resource for patients and families attending our FACTOR 2025 conference.
FACTOR 2025 registration is now open! Join us June 26-28th in Salt Lake City.
Check out the Scientific Program
There is a discounted conference room block at the beautiful Grand America Hotel. Book your room.
We have a limited number of FACTOR Travel Awards for OsteoWarrriors to attend. OsteoWarriors must be nominated by a healthcare provider. More info on eligibility and guidelines.
Brian Flesner, DVM, MS, DACVIM (Oncology), discusses the recently opened clinical trial studying an Autologous Cancer Vaccine with Checkpoint Inhibitor for the Treatment of Canine Osteosarcoma.
The purpose of this study is to evaluate the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine combined with a novel checkpoint inhibitor (CD200AR-L), compared to standard-of-care chemotherapy for the treatment of canine appendicular osteosarcoma (OSA). K9-ACV has safely been used in over 1,000 dogs, and the vaccine has been shown to display safety in a previous study (without the addition of the checkpoint inhibitor). By evaluating K9-ACV, this trial aims to advance safer, immune-based treatment options for canine cancer that may offer comparable or superior outcomes to chemotherapy.
Find more information about this study:
https://studypages.com/s/autologous-cancer-vaccine-with-checkpoint-inhibitor-for-treatment-of-canine-osteosarcoma-565406/
Adrienne Wright, adrienne@ardentanimalhealth.com, +1 (859) 619-5893
osTEAo co-hosts Mia and Sammy sit down with fellow OsteoWarriors Andrew and Mackenzie for a real, raw, and refreshingly honest convo about FOMO—Fear of Missing Out—as young adult cancer survivors. From missing prom and sports to navigating dating and college with a whole new perspective, these resilient humans get into what it actually feels like to rebuild a life after treatment.
They talk about setting boundaries on social media, finding new passions, and surrounding yourself with people who truly get it. They also dive into the hard but vital work of self-advocacy and honest communication.
💥 Expect wisdom, laughs, hard truths, and all the inspo. This episode is a must-listen for anyone figuring out how to live fully—even when it looks different than planned.
TJ Utset-Ward, MD, cirujano ortopédico del Nicklaus Children's Hospital, ofrece una descripción general de las opciones quirúrgicas y los avances en el osteosarcoma.
El tratamiento del osteosarcoma consiste en una combinación de quimioterapia y cirugía para extirpar el tumor. En la década de 1980, la amputación de extremidades se utilizaba en el 80 % de los casos. Hoy en día, gracias a los avances en las técnicas quirúrgicas, la tecnología y nuestro conocimiento del osteosarcoma, más del 90 % de los casos son susceptibles a una cirugía para preservar la extremidad. Hoy en día, los pacientes y sus familias pueden incluso elegir entre varias opciones, incluyendo reconstrucciones que se adaptan al crecimiento del niño. Analizaremos algunas de estas opciones y cirugías, así como los objetivos y prioridades de la cirugía de osteosarcoma.
El Dr. T.J. Utset-Ward es cirujano ortopédico pediátrico especializado en oncología ortopédica pediátrica en el Hospital Infantil Nicklaus. Es cubanoamericano, hispanohablante y nativo de la ciudad de Miami, y se siente honrado de servir a su comunidad como uno de los pocos cirujanos oncológicos ortopédicos del país dedicados exclusivamente al sarcoma pediátrico y adolescente. Obtuvo su título de médico en la Facultad de Medicina de la Universidad de Vanderbilt en Nashville, Tennessee. El Dr. Utset-Ward completó su residencia en cirugía ortopédica en la Facultad de Medicina de la Universidad de Chicago/UChicago en Illinois. Realizó una beca de investigación en oncología musculoesquelética en la Universidad Estatal de Ohio en Columbus, Ohio, y posteriormente amplió su formación con una beca de investigación en oncología ortopédica pediátrica en el Hospital Infantil Nationwide. Sus intereses clínicos y de investigación incluyen sarcomas óseos pediátricos, sarcomas de tejidos blandos, oncología en adolescentes y adultos jóvenes, impresión 3D, implantes y diseños personalizados para cada paciente, salvamento y reconstrucción de extremidades, alargamiento de extremidades, transporte óseo, exosomas y oncología de precisión. El Dr. Utset se ha unido a la comunidad de MiB y espera seguir apoyando los esfuerzos para ayudar a las familias que enfrentan el osteosarcoma. Vive en Miami con su esposa, la pediatra Leah Utset, y sus dos hijos.
The osteosarcoma community has the power to drive change in childhood cancer research! This important OsteoBites episode features Nancy Goodman, JD, Founder & Executive Director of Kids v Cancer, as she discusses how you can help advocate for the Give Kids a Chance Act—a crucial bill aimed at expanding access to novel combination therapies for kids with cancer.
The Give Kids a Chance Act is bipartisan legislation that builds on the RACE for Children Act by requiring pharmaceutical companies to evaluate promising multi-drug combinations in pediatric cancers when those drugs are being tested together in adults. Since many of the most effective cancer treatments involve drug combinations, this bill is essential to improving treatment options for children with osteosarcoma and other pediatric cancers.
Be a voice for change! Learn actionable ways to support this bill and ensure kids with cancer have access to more innovative therapies.